The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia
Open accessAbstract
Significant advances have been made in the last decade toward a better understanding of the disease pathogenesis and the development of novel therapies that target specific subsets of adult acute lymphoblastic leukemia (ALL). Risk‐adapted strategies are transforming the disease treatment and prognosis. With current treatment regimens, long‐term survival is achieved by approximately 50% of patients with B‐cell ALL, 50% to 60% of patients with Philadelphia chromosome–positive ALL, and approximately 80% of patients with Burkitt's leukemia. Genomic profiling in ALL has identified new prognostic markers, new therapeutic targets, and novel ALL subtypes. These may be amenable to future targeted therapies that can further improve outcomes. The early recognition of early precursor T‐cell ALL, a distinct pathobiological entity with a poor prognosis, is essential for the development of an effective clinical management strategy. The role of monoclonal antibodies and cytotoxic T‐cell therapies continues to be defined. Many of the approaches are currently being evaluated for ALL salvage. Their incorporation into frontline adult ALL therapy, in concomitant or sequential strategies, may increase the cure rates to levels achieved in pediatric ALL and may reduce the need for prolonged intensive and maintenance chemotherapy. Cancer 2015;121:2517–2528. © 2015 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Saglio, G., Kim, D.-W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., Pasquini, R., Clark, R. E., Hochhaus, A., Hughes, T. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912614 · Cited by 1,678
Self-citationThe genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S. L., Payne-Turner, D., Easton, J., Chen, X., Wang, J., Rusch, M., et al. (2012) · Nature · doi:10.1038/nature10725 · Cited by 1,596
Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
Mullighan, C. G., Su, X., Zhang, J., Radtke, I., Phillips, L. A. A., Miller, C. B., Ma, J., Liu, W., Cheng, C., Schulman, B. A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808253 · Cited by 1,422
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
Roberts, K. G., Li, Y., Payne-Turner, D., Harvey, R. C., Yang, Y.-L., Pei, D., McCastlain, K., Ding, L., Lu, C., Song, G., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403088 · Cited by 1,377
Self-citationTopp, M. S., Gökbuget, N., Stein, A. S., Zugmaier, G., O'Brien, S., Bargou, R. C., Dombret, H., Fielding, A. K., Heffner, L., Larson, R. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71170-2 · Cited by 1,269
Self-citationO'Hare, T., Shakespeare, W. C., Zhu, X., Eide, C. A., Rivera, V. M., Wang, F., Adrian, L. T., Zhou, T., Huang, W.-S., Xu, Q., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.028 · Cited by 1,259
Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation
Pui, C.-H., Campana, D., Pei, D., Bowman, W. P., Sandlund, J. T., Kaste, S. C., Ribeiro, R. C., Rubnitz, J. E., Raimondi, S. C., Onciu, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900386 · Cited by 1,215
Inaba, H., Greaves, M., & Mullighan, C. G. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62187-4 · Cited by 1,074
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia
Coustan-Smith, E., Mullighan, C. G., Onciu, M., Behm, F. G., Raimondi, S. C., Pei, D., Cheng, C., Su, X., Rubnitz, J. E., Basso, G., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70314-0 · Cited by 1,019
Den Boer, M. L., van Slegtenhorst, M., De Menezes, R. X., Cheok, M. H., Buijs-Gladdines, J. G., Peters, S. T., Van Zutven, L. J., Beverloo, H. B., Van der Spek, P. J., Escherich, G., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70339-5 · Cited by 930
Topp, M. S., Kufer, P., Gökbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H.-A., Raff, T., Viardot, A., Schmid, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7270 · Cited by 913
Borowitz, M. J., Devidas, M., Hunger, S. P., Bowman, W. P., Carroll, A. J., Carroll, W. L., Linda, S., Martin, P. L., Pullen, D. J., Viswanatha, D., et al. (2008) · Blood · doi:10.1182/blood-2008-01-132837 · Cited by 842
Conter, V., Bartram, C. R., Valsecchi, M. G., Schrauder, A., Panzer-Grümayer, R., Möricke, A., Aricò, M., Zimmermann, M., Mann, G., De Rossi, G., et al. (2010) · Blood · doi:10.1182/blood-2009-10-248146 · Cited by 785
Goldstone, A. H., Richards, S. M., Lazarus, H. M., Tallman, M. S., Buck, G., Fielding, A. K., Burnett, A. K., Chopra, R., Wiernik, P. H., Foroni, L., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116582 · Cited by 778
Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kantarjian, H., Shah, N. P., Bixby, D., Mauro, M. J., Flinn, I., O'Hare, T., Hu, S., Narasimhan, N. I., Rivera, V. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205127 · Cited by 769
Self-citationThe genomic landscape of hypodiploid acute lymphoblastic leukemia
Holmfeldt, L., Wei, L., Diaz-Flores, E., Walsh, M., Zhang, J., Ding, L., Payne-Turner, D., Churchman, M., Andersson, A., Chen, S.-C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2532 · Cited by 731
Roberts, K. G., Morin, R. D., Zhang, J., Hirst, M., Zhao, Y., Su, X., Chen, S.-C., Payne-Turner, D., Churchman, M. L., Harvey, R. C., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.005 · Cited by 714
Topp, M. S., Gökbuget, N., Zugmaier, G., Klappers, P., Stelljes, M., Neumann, S., Viardot, A., Marks, R., Diedrich, H., Faul, C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.3247 · Cited by 658
Kantarjian, H., Thomas, D., O'Brien, S., Cortes, J., Giles, F., Jeha, S., Bueso‐Ramos, C. E., Pierce, S., Shan, J., Koller, C., et al. (2004) · Cancer · doi:10.1002/cncr.20668 · Cited by 638
Self-citationRearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia
Mullighan, C. G., Collins-Underwood, J. R., Phillips, L. A. A., Loudin, M. G., Liu, W., Zhang, J., Ma, J., Coustan-Smith, E., Harvey, R. C., Willman, C. L., et al. (2009) · Nature Genetics · doi:10.1038/ng.469 · Cited by 623
Kantarjian, H. M., Shah, N. P., Cortes, J. E., Baccarani, M., Agarwal, M. B., Undurraga, M. S., Wang, J., Kassack Ipiña, J. J., Kim, D.-W., Ogura, M., et al. (2012) · Blood · doi:10.1182/blood-2011-08-376087 · Cited by 610
Self-citationHarvey, R. C., Mullighan, C. G., Chen, I.-M., Wharton, W., Mikhail, F. M., Carroll, A. J., Kang, H., Liu, W., Dobbin, K. K., Smith, M. A., et al. (2010) · Blood · doi:10.1182/blood-2009-09-245944 · Cited by 574
Huguet, F., Leguay, T., Raffoux, E., Thomas, X., Beldjord, K., Delabesse, E., Chevallier, P., Buzyn, A., Delannoy, A., Chalandon, Y., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.6916 · Cited by 567
Thomas, D. A., Faderl, S., O'Brien, S., Bueso‐Ramos, C., Cortes, J., Garcia‐Manero, G., Giles, F. J., Verstovsek, S., Wierda, W. G., Pierce, S. A., et al. (2006) · Cancer · doi:10.1002/cncr.21776 · Cited by 566
Self-citationBrüggemann, M., Raff, T., Flohr, T., Gökbuget, N., Nakao, M., Droese, J., Lüschen, S., Pott, C., Ritgen, M., Scheuring, U., et al. (2006) · Blood · doi:10.1182/blood-2005-07-2708 · Cited by 537
Stock, W., La, M., Sanford, B., Bloomfield, C. D., Vardiman, J. W., Gaynon, P., Larson, R. A., & Nachman, J. (2008) · Blood · doi:10.1182/blood-2008-01-130237 · Cited by 534
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?
Pui, C.-H., Mullighan, C. G., Evans, W. E., & Relling, M. V. (2012) · Blood · doi:10.1182/blood-2012-05-378943 · Cited by 500
Russell, L. J., Capasso, M., Vater, I., Akasaka, T., Bernard, O. A., Calasanz, M. J., Chandrasekaran, T., Chapiro, E., Gesk, S., Griffiths, M., et al. (2009) · Blood · doi:10.1182/blood-2009-03-208397 · Cited by 498
Gökbuget, N., Kneba, M., Raff, T., Trautmann, H., Bartram, C.-R., Arnold, R., Fietkau, R., Freund, M., Ganser, A., Ludwig, W.-D., et al. (2012) · Blood · doi:10.1182/blood-2011-09-377713 · Cited by 493
Topp, M. S., Gökbuget, N., Zugmaier, G., Degenhard, E., Goebeler, M.-E., Klinger, M., Neumann, S. A., Horst, H. A., Raff, T., Viardot, A., et al. (2012) · Blood · doi:10.1182/blood-2012-07-441030 · Cited by 474
Gökbuget, N., Stanze, D., Beck, J., Diedrich, H., Horst, H.-A., Hüttmann, A., Kobbe, G., Kreuzer, K.-A., Leimer, L., Reichle, A., et al. (2012) · Blood · doi:10.1182/blood-2011-12-399287 · Cited by 472
Bassan, R., Spinelli, O., Oldani, E., Intermesoli, T., Tosi, M., Peruta, B., Rossi, G., Borlenghi, E., Pogliani, E. M., Terruzzi, E., et al. (2009) · Blood · doi:10.1182/blood-2008-11-185132 · Cited by 430
Thomas, D. A., O'Brien, S., Faderl, S., Garcia-Manero, G., Ferrajoli, A., Wierda, W., Ravandi, F., Verstovsek, S., Jorgensen, J. L., Bueso-Ramos, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9456 · Cited by 416
Self-citationKantarjian, H., Thomas, D., Jorgensen, J., Jabbour, E., Kebriaei, P., Rytting, M., York, S., Ravandi, F., Kwari, M., Faderl, S., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70386-2 · Cited by 412
Self-citationHu, Y., Liu, Y., Pelletier, S., Buchdunger, E., Warmuth, M., Fabbro, D., Hallek, M., Van Etten, R. A., & Li, S. (2004) · Nature Genetics · doi:10.1038/ng1343 · Cited by 405
Fielding, A. K., Rowe, J. M., Buck, G., Foroni, L., Gerrard, G., Litzow, M. R., Lazarus, H., Luger, S. M., Marks, D. I., McMillan, A. K., et al. (2014) · Blood · doi:10.1182/blood-2013-09-529008 · Cited by 378
Low-Intensity Therapy in Adults with Burkitt's Lymphoma
Dunleavy, K., Pittaluga, S., Shovlin, M., Steinberg, S. M., Cole, D., Grant, C., Widemann, B., Staudt, L. M., Jaffe, E. S., Little, R. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1308392 · Cited by 360
Blinatumomab: A historical perspective
Nagorsen, D., Kufer, P., Baeuerle, P. A., & Bargou, R. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.013 · Cited by 355
Ravandi, F., O'Brien, S., Thomas, D., Faderl, S., Jones, D., Garris, R., Dara, S., Jorgensen, J., Kebriaei, P., Champlin, R., et al. (2010) · Blood · doi:10.1182/blood-2009-12-261586 · Cited by 348
Self-citationHertzberg, L., Vendramini, E., Ganmore, I., Cazzaniga, G., Schmitz, M., Chalker, J., Shiloh, R., Iacobucci, I., Shochat, C., Zeligson, S., et al. (2010) · Blood · doi:10.1182/blood-2009-08-235408 · Cited by 346
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia
Yoda, A., Yoda, Y., Chiaretti, S., Bar-Natan, M., Mani, K., Rodig, S. J., West, N., Xiao, Y., Brown, J. R., Mitsiades, C., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911726107 · Cited by 340
Advani, A., Coiffier, B., Czuczman, M. S., Dreyling, M., Foran, J., Gine, E., Gisselbrecht, C., Ketterer, N., Nasta, S., Rohatiner, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1900 · Cited by 336
Kantarjian, H., Thomas, D., Jorgensen, J., Kebriaei, P., Jabbour, E., Rytting, M., York, S., Ravandi, F., Garris, R., Kwari, M., et al. (2013) · Cancer · doi:10.1002/cncr.28136 · Cited by 306
Self-citationHoelzer, D., Walewski, J., Döhner, H., Viardot, A., Hiddemann, W., Spiekermann, K., Serve, H., Dührsen, U., Hüttmann, A., Thiel, E., et al. (2014) · Blood · doi:10.1182/blood-2014-03-563627 · Cited by 289
Bassan, R., Rossi, G., Pogliani, E. M., Di Bona, E., Angelucci, E., Cavattoni, I., Lambertenghi-Deliliers, G., Mannelli, F., Levis, A., Ciceri, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1287 · Cited by 272
Tavernier, E., Boiron, J.-M., Huguet, F., Bradstock, K., Vey, N., Kovacsovics, T., Delannoy, A., Fegueux, N., Fenaux, P., Stamatoullas, A., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404824 · Cited by 256
Roberts, K. G., Pei, D., Campana, D., Payne-Turner, D., Li, Y., Cheng, C., Sandlund, J. T., Jeha, S., Easton, J., Becksfort, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.4105 · Cited by 256
Raff, T., Gökbuget, N., Lüschen, S., Reutzel, R., Ritgen, M., Irmer, S., Böttcher, S., Horst, H.-A., Kneba, M., Hoelzer, D., et al. (2007) · Blood · doi:10.1182/blood-2006-07-037093 · Cited by 240
Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations
Neumann, M., Heesch, S., Schlee, C., Schwartz, S., Gökbuget, N., Hoelzer, D., Konstandin, N. P., Ksienzyk, B., Vosberg, S., Graf, A., et al. (2013) · Blood · doi:10.1182/blood-2012-11-465138 · Cited by 217
Ravandi, F., Jorgensen, J. L., Thomas, D. A., O’Brien, S., Garris, R., Faderl, S., Huang, X., Wen, S., Burger, J. A., Ferrajoli, A., et al. (2013) · Blood · doi:10.1182/blood-2012-11-466482 · Cited by 205
Self-citationSive, J. I., Buck, G., Fielding, A., Lazarus, H. M., Litzow, M. R., Luger, S., Marks, D. I., McMillan, A., Moorman, A. V., Richards, S. M., et al. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09095.x · Cited by 198
Thomas, D. A., Kantarjian, H., Smith, T. L., Koller, C., Cortes, J., O'Brien, S., Giles, F. J., Gajewski, J., Pierce, S., & Keating, M. J. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991001)86:7<1216::aid-cncr17>3.0.co;2-o · Cited by 196
Self-citationMinimal Residual Disease in Acute Lymphoblastic Leukemia
Campana, D. (2010) · Hematology · doi:10.1182/asheducation-2010.1.7 · Cited by 187
Schmidt, A., Rousselot, P. H., Chalandon, Y., Cayuela, J., Hayette, S., Vekemans, M., Escoffre‐Barbe, M., Huguet, F., Réa, D., Delannoy, A., et al. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.08.021 · Cited by 157
O'Brien, S. M., Thomas, D. A., Ravandi, F., Faderl, S. H., Pierce, S. A., & Kantarjian, H. M. (2008) · Cancer · doi:10.1002/cncr.23819 · Cited by 133
Self-citationStock, W., Luger, S. M., Advani, A. S., Geyer, S. M., Harvey, R. C., Mullighan, C. G., Willman, C. L., Malnassy, G., Parker, E., Laumann, K. M., et al. (2014) · Blood · doi:10.1182/blood.v124.21.796.796 · Cited by 105
Rytting, M., Thomas, D. A., O'Brien, S. M., Ravandi‐Kashani, F., Jabbour, E. J., Franklin, A. R. K., Kadia, T. M., Pemmaraju, N., Daver, N. G., Ferrajoli, A., et al. (2014) · Cancer · doi:10.1002/cncr.28930 · Cited by 100
Self-citationRizzieri, D. A., Johnson, J. L., Byrd, J. C., Lozanski, G., Blum, K. A., Powell, B. L., Shea, T. C., Nattam, S. R., Hoke, E. E., Cheson, B. D., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12736 · Cited by 99
Chemoimmunotherapy in acute lymphoblastic leukemia
Hoelzer, D. F., & Gökbuget, N. (2011) · Blood Reviews · doi:10.1016/j.blre.2011.08.001 · Cited by 98
Mühlbacher, V., Zenger, M., Schnittger, S., Weißmann, S., Kunze, F., Kohlmann, A., Bellos, F., Kern, W., Haferlach, T., & Haferlach, C. (2014) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22163 · Cited by 97
Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia
Thomas, X. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.679359 · Cited by 29
Rousselot, P. H., Coudé, M., Huguet, F., et al. (2012) · Blood · doi:10.1182/blood.v120.21.666.666 · Cited by 25
Turtle, C. J., Sommermeyer, D., Berger, C., Hudecek, M., Shank, D. M., Steevens, N. N., Budiarto, T. M., Karimi, M., Chaney, C. N., DeVito, A. M., et al. (2014) · Blood · doi:10.1182/blood.v124.21.384.384 · Cited by 17
Cited by
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H., Stein, A., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J.-M., Wei, A., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,143
Self-citationAcute lymphoblastic leukemia: a comprehensive review and 2017 update
Terwilliger, T., & Abdul-Hay, M. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.53 · Cited by 1,288
MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches
Winters, A. C., & Bernt, K. M. (2017) · Frontiers in Pediatrics · doi:10.3389/fped.2017.00004 · Cited by 405
Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia
Liu, Y.-F., Wang, B.-Y., Zhang, W.-N., Huang, J.-Y., Li, B.-S., Zhang, M., Jiang, L., Li, J.-F., Wang, M.-J., Dai, Y.-J., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.04.038 · Cited by 333
Adult Acute Lymphoblastic Leukemia
Paul, S., Kantarjian, H., & Jabbour, E. J. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.09.010 · Cited by 275
Self-citation
Metadata
- Authors
- Jabbour, E., O'Brien, S., Konopleva, M., & Kantarjian, H.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2015-04-17
- Volume
- 121
- Issue
- 15
- Pages
- 2517-2528
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1879221139
- Cited by
- 285
- References
- 71
- FWCI
- 18.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.